While Ireland weathered the storms of Brexit with characteristic resilience, the specter of American tariffs now looms over the Emerald Isle like a particularly unwelcome houseguest—one threatening to raid the economic pantry and leave nothing but crumbs.
The government has already slashed its 2025 corporation tax forecast by €2 billion, bringing expectations down to €29 billion—a sobering reality check that arrived before the tariffs even properly kicked in.
Government slashes 2025 corporation tax forecast by €2 billion—a sobering reality check before tariffs even properly kick in.
Currently, only 2-3% of Irish exports face Trump’s baseline 10% tariff, with pharmaceuticals enjoying a blessed exemption that shields the country’s most lucrative sector. Yet multinationals are already stockpiling pharmaceuticals in the United States ahead of potential policy shifts, betraying their own anxiety about the future.
But here’s where the plot thickens: those safe harbors might not remain safe for long. The threat of expanded tariffs hangs in the air like dampness before rain, making businesses jittery enough to delay investments—particularly worrying given Ireland’s strong US export orientation that makes it the most exposed country in Europe to Trump’s trade warfare. The tech sector could experience rapid company relocations if trade tensions escalate further, a threat that remains largely unaddressed in economic impact discussions.
